Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of TAS-102 in Advanced Solid Tumors
NCT02031055Phase 1Completed
- Sponsor
- Taiho Oncology
- Start
- Feb 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trifluridine + tipiracil in solid tumor (advanced stage) (2 arms), sponsored by Taiho Oncology. Primary endpoints: Urinary, fecal, and respiratory excretion of 14C from FTD and urinary and fecal excretion of 14C from TPI, PK parameters of total radioactivity (AUC0-inf, AUC0-last, Cmax, Tmax, and T1/2) in whole blood and plasma and 2 more. Started Feb 2014; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02031055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031055.